Published in MBio on December 13, 2011
Mosquito bite delivery of dengue virus enhances immunogenicity and pathogenesis in humanized mice. J Virol (2012) 1.36
Transmission-blocking antibodies against mosquito C-type lectins for dengue prevention. PLoS Pathog (2014) 0.92
Mannose binding lectin is required for alphavirus-induced arthritis/myositis. PLoS Pathog (2012) 0.92
Complement-related proteins control the flavivirus infection of Aedes aegypti by inducing antimicrobial peptides. PLoS Pathog (2014) 0.90
Role of complement in dengue virus infection: protection or pathogenesis? MBio (2012) 0.83
Host biomarkers distinguish dengue from leptospirosis in Colombia: a case-control study. BMC Infect Dis (2014) 0.80
Serum proteome changes in dengue virus-infected patients from a dengue-endemic area of India: towards new molecular targets? OMICS (2012) 0.78
Secreted NS1 Protects Dengue Virus from Mannose-Binding Lectin-Mediated Neutralization. J Immunol (2016) 0.77
C1q binding to dengue virus decreases levels of infection and inflammatory molecules transcription in THP-1 cells. Virus Res (2013) 0.76
Elevated levels of vitamin D and deficiency of mannose binding lectin in dengue hemorrhagic fever. Virol J (2012) 0.76
Synergy between the classical and alternative pathways of complement is essential for conferring effective protection against the pandemic influenza A(H1N1) 2009 virus infection. PLoS Pathog (2017) 0.75
The Complement System in Flavivirus Infections. Front Microbiol (2017) 0.75
Complement Evasion Strategies of Viruses: An Overview. Front Microbiol (2017) 0.75
Dengue Virus Glycosylation: What Do We Know? Front Microbiol (2017) 0.75
Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell (2002) 9.13
A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg (1988) 8.54
DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med (2003) 4.69
Epidemiology of inapparent and symptomatic acute dengue virus infection: a prospective study of primary school children in Kamphaeng Phet, Thailand. Am J Epidemiol (2002) 4.62
Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev (2009) 3.61
Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol (1995) 3.30
Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol (2008) 3.27
Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol (2006) 3.23
A human serum mannose-binding protein inhibits in vitro infection by the human immunodeficiency virus. J Exp Med (1989) 2.95
Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. J Infect Dis (2006) 2.82
Assembly and maturation of the flavivirus Kunjin virus appear to occur in the rough endoplasmic reticulum and along the secretory pathway, respectively. J Virol (2001) 2.81
Trends in patterns of dengue transmission over 4 years in a pediatric cohort study in Nicaragua. J Infect Dis (2010) 2.80
Dissecting the cell entry pathway of dengue virus by single-particle tracking in living cells. PLoS Pathog (2008) 2.77
The potential pathogenic role of complement in dengue hemorrhagic shock syndrome. N Engl J Med (1973) 2.64
Mannose-binding lectin deficiency--revisited. Mol Immunol (2003) 2.52
Identification of distinct antigenic determinants on dengue-2 virus using monoclonal antibodies. Am J Trop Med Hyg (1982) 2.41
Phylogenetic relationships of flaviviruses correlate with their epidemiology, disease association and biogeography. J Gen Virol (2001) 2.19
Cryo-EM reconstruction of dengue virus in complex with the carbohydrate recognition domain of DC-SIGN. Cell (2006) 2.08
Impact of mannose-binding lectin on susceptibility to infectious diseases. Clin Infect Dis (2003) 2.08
Mannose-binding lectin and innate immunity. Immunol Rev (2009) 2.08
Clinical spectrum and management of dengue haemorrhagic fever. Southeast Asian J Trop Med Public Health (1987) 1.90
A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus. PLoS Pathog (2011) 1.70
Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2. J Clin Invest (2006) 1.69
Role of dendritic cells in antibody-dependent enhancement of dengue virus infection. J Virol (2008) 1.65
Complement activating soluble pattern recognition molecules with collagen-like regions, mannan-binding lectin, ficolins and associated proteins. Mol Immunol (2007) 1.65
Susceptibility to dengue hemorrhagic fever in vietnam: evidence of an association with variation in the vitamin d receptor and Fc gamma receptor IIa genes. Am J Trop Med Hyg (2002) 1.55
Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step. J Virol (2011) 1.49
Complement-dependent neutralization of influenza virus by a serum mannose-binding lectin. J Gen Virol (1994) 1.42
Flavivirus structure and membrane fusion. Adv Virus Res (2003) 1.39
Critical issues in dengue vaccine development. Curr Opin Infect Dis (2011) 1.39
Complement and viral pathogenesis. Virology (2011) 1.32
Complement and dengue haemorrhagic fever/shock syndrome. Southeast Asian J Trop Med Public Health (1987) 1.25
Mannose-binding lectin binds to Ebola and Marburg envelope glycoproteins, resulting in blocking of virus interaction with DC-SIGN and complement-mediated virus neutralization. J Gen Virol (2005) 1.24
Disease-causing mutations in genes of the complement system. Am J Hum Genet (2011) 1.24
Genetic, structural and functional diversities of human complement components C4A and C4B and their mouse homologues, Slp and C4. Int Immunopharmacol (2001) 1.23
Complement activation upon binding of mannan-binding protein to HIV envelope glycoproteins. AIDS (1993) 1.21
Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection. J Infect Dis (2005) 1.19
Mannan-binding-lectin-associated serine proteases, characteristics and disease associations. Springer Semin Immunopathol (2005) 1.17
The lectin pathway of complement activation contributes to protection from West Nile virus infection. Virology (2011) 1.16
Mannose-binding lectin in chronic hepatitis B virus infection. Hepatology (2005) 1.15
The complement response against an oncolytic virus is species-specific in its activation pathways. Mol Ther (2002) 1.14
MBL2 gene polymorphisms protect against development of thrombocytopenia associated with severe dengue phenotype. Hum Immunol (2008) 1.14
Human mannan-binding lectin inhibits the infection of influenza A virus without complement. Immunology (1999) 1.13
Mannose-binding lectin 2 gene polymorphism in recurrent herpes simplex virus 2 infection. Hum Immunol (2009) 1.10
Mannan-specific immunoglobulin G antibodies in normal human serum mediate classical pathway initiation of C3 binding to Candida albicans. Infect Immun (1997) 1.05
Direct complement restriction of flavivirus infection requires glycan recognition by mannose-binding lectin. Cell Host Microbe (2010) 1.03
Mannan-binding lectin modulates the response to HSV-2 infection. Clin Exp Immunol (2004) 1.02
Cleavage of the third component of complement (C3) by mannose-binding protein-associated serine protease (MASP) with subsequent complement activation. Immunobiology (1995) 1.00
Mannan-specific immunoglobulin G antibodies in normal human serum accelerate binding of C3 to Candida albicans via the alternative complement pathway. Infect Immun (1998) 0.98
N-linked glycans on dengue viruses grown in mammalian and insect cells. J Gen Virol (2009) 0.97
Recombinant expression of human mannan-binding lectin. Int Immunopharmacol (2001) 0.96
Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry. Protein Cell (2010) 0.90
Aspergillus conidia activate the complement by the mannan-binding lectin C2 bypass mechanism. J Immunol (2008) 0.87
Association between mannose-binding lectin and HIV infection and progression in a Chinese population. Mol Immunol (2009) 0.86
Mannose-binding lectin MBL2 gene polymorphisms and outcome of hepatitis C virus-infected patients. J Clin Immunol (2008) 0.83
Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc Natl Acad Sci U S A (2006) 8.27
Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science (2008) 7.87
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature (2012) 5.49
Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med (2005) 5.09
DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med (2003) 4.69
Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood (2006) 4.51
Herpesvirus latency confers symbiotic protection from bacterial infection. Nature (2007) 4.27
Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity (2004) 4.11
Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J Virol (2005) 3.59
Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature (2005) 3.51
2'-O methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature (2010) 3.49
The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe (2010) 3.48
Role of CD8+ T cells in control of West Nile virus infection. J Virol (2004) 3.40
Neuronal CXCL10 directs CD8+ T-cell recruitment and control of West Nile virus encephalitis. J Virol (2005) 3.31
Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol (2008) 3.27
The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe (2007) 3.25
Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol (2006) 3.23
Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog (2010) 3.16
Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion. J Virol (2006) 3.15
PKR and RNase L contribute to protection against lethal West Nile Virus infection by controlling early viral spread in the periphery and replication in neurons. J Virol (2006) 3.13
Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood (2008) 3.10
Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol (2007) 2.89
Genetic and functional analyses of membrane cofactor protein (CD46) mutations in atypical hemolytic uremic syndrome. J Am Soc Nephrol (2006) 2.88
Ribose 2'-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nat Immunol (2011) 2.85
Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature (2003) 2.83
Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A (2003) 2.79
Toll-like receptor 3 has a protective role against West Nile virus infection. J Virol (2008) 2.62
Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. N Engl J Med (2004) 2.62
Six RNA viruses and forty-one hosts: viral small RNAs and modulation of small RNA repertoires in vertebrate and invertebrate systems. PLoS Pathog (2010) 2.62
IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat Immunol (2012) 2.62
Crystal structure of the West Nile virus envelope glycoprotein. J Virol (2006) 2.61
A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology (2005) 2.60
Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood (2004) 2.58
Resistance to alpha/beta interferon is a determinant of West Nile virus replication fitness and virulence. J Virol (2006) 2.57
Cell-specific IRF-3 responses protect against West Nile virus infection by interferon-dependent and -independent mechanisms. PLoS Pathog (2007) 2.54
Adenovirus type 11 uses CD46 as a cellular receptor. J Virol (2003) 2.52
CD4+ T-cell responses are required for clearance of West Nile virus from the central nervous system. J Virol (2006) 2.44
Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A (2012) 2.42
West Nile virus infection and immunity. Nat Rev Microbiol (2013) 2.40
IPS-1 is essential for the control of West Nile virus infection and immunity. PLoS Pathog (2010) 2.39
Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology (2005) 2.36
C-terminal truncations in human 3'-5' DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat Genet (2007) 2.35
CD8+ T cells require perforin to clear West Nile virus from infected neurons. J Virol (2006) 2.31
Induction of epitope-specific neutralizing antibodies against West Nile virus. J Virol (2007) 2.30
T-cell regulation: with complements from innate immunity. Nat Rev Immunol (2006) 2.27
Infection and injury of neurons by West Nile encephalitis virus. J Virol (2003) 2.25
Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect Dis (2010) 2.24
Tregs control the development of symptomatic West Nile virus infection in humans and mice. J Clin Invest (2009) 2.18
Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe (2008) 2.16
Immunology of age-related macular degeneration. Nat Rev Immunol (2013) 2.14
Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol (2010) 2.14
Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. J Virol (2003) 2.13
Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J Exp Med (2006) 2.11
The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog (2010) 2.03
Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog (2008) 2.00
Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J Immunol (2007) 2.00
Secreted NS1 of dengue virus attaches to the surface of cells via interactions with heparan sulfate and chondroitin sulfate E. PLoS Pathog (2007) 1.97
Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. J Virol (2005) 1.97
West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H. Proc Natl Acad Sci U S A (2006) 1.96
Induction of IFN-beta and the innate antiviral response in myeloid cells occurs through an IPS-1-dependent signal that does not require IRF-3 and IRF-7. PLoS Pathog (2009) 1.95
In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis (2011) 1.92
Interferon regulatory factor IRF-7 induces the antiviral alpha interferon response and protects against lethal West Nile virus infection. J Virol (2008) 1.92
Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms. J Virol (2006) 1.91
Antigen-specific cytotoxic T lymphocytes protect against lethal West Nile virus encephalitis. Eur J Immunol (2007) 1.89
Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. Invest Ophthalmol Vis Sci (2009) 1.86
Caspase 3-dependent cell death of neurons contributes to the pathogenesis of West Nile virus encephalitis. J Virol (2006) 1.86
Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. EMBO J (2009) 1.85
Gamma interferon plays a crucial early antiviral role in protection against West Nile virus infection. J Virol (2006) 1.84
Interferon-induced Ifit2/ISG54 protects mice from lethal VSV neuropathogenesis. PLoS Pathog (2012) 1.84
Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters. J Infect Dis (2006) 1.84
West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody. Proc Natl Acad Sci U S A (2006) 1.83
Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol Immunol (2006) 1.82
CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes. J Allergy Clin Immunol (2006) 1.81
Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration. Nat Genet (2013) 1.77
Antagonism of the complement component C4 by flavivirus nonstructural protein NS1. J Exp Med (2010) 1.76
Dengue structure differs at the temperatures of its human and mosquito hosts. Proc Natl Acad Sci U S A (2013) 1.75
Complement activation is required for induction of a protective antibody response against West Nile virus infection. J Virol (2005) 1.75
Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus. J Virol (2005) 1.72
A viral RNA structural element alters host recognition of nonself RNA. Science (2014) 1.71
Axonal transport mediates West Nile virus entry into the central nervous system and induces acute flaccid paralysis. Proc Natl Acad Sci U S A (2007) 1.71
Genetically determined high serum levels of mannose-binding lectin and agalactosyl IgG are associated with ischemic heart disease in rheumatoid arthritis. Arthritis Rheum (2007) 1.70
Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev Mol Med (2008) 1.67
IRF-3, IRF-5, and IRF-7 coordinately regulate the type I IFN response in myeloid dendritic cells downstream of MAVS signaling. PLoS Pathog (2013) 1.67
Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells. Nat Immunol (2010) 1.67
Mannose-binding lectin engagement with late apoptotic and necrotic cells. Eur J Immunol (2003) 1.66
Role of dendritic cells in antibody-dependent enhancement of dengue virus infection. J Virol (2008) 1.65
Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step. J Virol (2009) 1.65
2'-O methylation of the viral mRNA cap by West Nile virus evades ifit1-dependent and -independent mechanisms of host restriction in vivo. PLoS Pathog (2012) 1.62
Nondegradative role of Atg5-Atg12/ Atg16L1 autophagy protein complex in antiviral activity of interferon gamma. Cell Host Microbe (2012) 1.61
CXCR3 mediates region-specific antiviral T cell trafficking within the central nervous system during West Nile virus encephalitis. J Immunol (2008) 1.61
CXCR4 antagonism increases T cell trafficking in the central nervous system and improves survival from West Nile virus encephalitis. Proc Natl Acad Sci U S A (2008) 1.60
Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J Virol (2010) 1.58
Hepatic IL-17 responses in human and murine primary biliary cirrhosis. J Autoimmun (2008) 1.57
Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354. Proc Natl Acad Sci U S A (2010) 1.57
Properdin: emerging roles of a pattern-recognition molecule. Annu Rev Immunol (2010) 1.55
Differential innate immune response programs in neuronal subtypes determine susceptibility to infection in the brain by positive-stranded RNA viruses. Nat Med (2013) 1.55